A panel of experts will advise the Federal and Drug Administration on Thursday on whether to approve Luxturna, a one-time shot that would repair a defective gene that causes inherited child blindness. If approved, it would be the first legal gene therapy on the market in the U.S.
FDA To Review Experimental Gene Therapy To Treat Childhood Blindness
By editor • Oct 12, 2017
Originally published on October 12, 2017 3:22 pm
Copyright 2018 NPR. To see more, visit http://www.npr.org/.